https://neuropro.io/key-milestone/neuropro-initiates-phase-1-october-2022/ 2024-01-23T05:09:29+00:00 https://neuropro.io/key-milestone/neuropro-files-ind-with-fda-to-initiate-phase-1-study-august-2022/ 2024-01-23T05:09:38+00:00 https://neuropro.io/key-milestone/neuropro-closes-for-preclinical-development-and-phase-1-study-2019/ 2024-01-23T05:18:45+00:00 https://neuropro.io/key-milestone/neuropro-completes-npt-2042-phase-1-study-march-2023/ 2024-01-23T11:57:34+00:00 https://neuropro.io/wp-content/uploads/2023/05/Layer-24.webp https://neuropro.io/key-milestone/neuropro-secures-5m-in-equity-funding-to-prepare-for-phase-2-february-2023/ 2024-05-14T18:28:16+00:00 https://neuropro.io/wp-content/uploads/2023/06/Group-486.png https://neuropro.io/key-milestone/march-2024-neuropro-therapeutics-announces-23-million-financing-to-advance-npt-2042-epilepsy-treatment/ 2024-05-14T18:39:10+00:00 https://neuropro.io/key-milestone/december-2023-neuropro-presents-phase-2-study-design-at-the-american-epilepsy-society-aes-meeting/ 2024-08-22T16:09:23+00:00 https://neuropro.io/key-milestone/august-2024-neuropro-initiates-a-photoparoxysmal-eeg-response-study-in-collaboration-with-the-epilepsy-study-consortium-inc/ 2024-08-22T18:49:53+00:00 https://neuropro.io/key-milestone/january-2025-neuropro-initiates-a-study-evaluating-npt-2042-versus-placebo-in-subjects-with-genetic-generalized-epilepsy-gge-and-absence-seizures/ 2026-06-10T15:50:49+00:00